A leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
We are in the midst of a worsening global antimicrobials resistance (AMR) crisis. There is an urgent need for new classes of antibacterial, antifungal and other antimicrobial treatments to address range of challenging infectious diseases that can no longer be resolved with existing drugs. NovaBiotics is a leading innovator in the anti-infectives space and we are designing and developing new medicines that are potential solutions not only to the AMR crisis, but also for complex diseases with an infectious component such as the respiratory infections associated with cystic fibrosis (CF).
NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to clinic of its portfolio of therapeutic candidates. These first in class antimicrobials have been developed from our two proprietary technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.
Clinical Stage Products
NM002 (Nylexa®) and NM001 (Lynovex®) are therapy candidates that have been generated from NovaBiotics’ aminothiol technology platform. NM002 (Nylexa®) for COVID19 is a unique antimicrobial-immunomodulator that will be tested in a multi-country, phase 3 platform clinical trial in severe-moderate COVID19 patients. NM002 (Nylexa®) is also being developed for bacterial infections, drug resistant or otherwise recalcitrant bacterial infections and ‘supercharges’ the activity of existing antibiotics, re-establishing their effectiveness. Lynovex in oral and inhaled form are novel, highly differentiated therapies for the treatment of cystic fibrosis-associated lung disease for all CF genotypes (they are not a mutation-specific intervention).
NP213 (Novexatin®) is a step change in the treatment of nail fungus (onychomycosis) and has been derived from the Company’s propriety antimicrobial peptide platform . Based on the results of our clinical studies, Novexatin is the first topical treatment to resolve infection and deliver rapid cosmetic benefits after only 28 days of daily application.
Preclinical Candidates and Pipeline
NovaBiotics is developing a robust pipeline of antifungal and antibacterial candidates from both its aminothiol and peptide platforms including NP339 and NP432 from its proprietary antimicrobial peptide technology platform.
A novel Approach to Antimicrobial Drug Development
Rational drug design and ‘smart immunology’ are the basis of our unique design of novel antimicrobial therapies. We have engineered our platforms and therapy candidates on the natural infection fighting agents that are produced by the body’s immune system in response to infection or inflammation. This is a low risk approach because we already know the mechanism of action of our drug candidates.